Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUGN0J)

Drug Name
CDX-1140 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMUGN0J

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Agonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD40L receptor (CD40) DTT CD40 4.629 4.991 5.53 3.385
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD40L receptor (CD40) DTT CD40 4.61E-01 0.56 0.5
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03329950) A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245.